Mezzanzanica Delia
12PUBLICATIONS
70CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (12)
Sort by Publication Date:
|Sep 23, 2022
Analysis of A Disintegrin and Metalloprotease 17 (ADAM17) Expression as a Prognostic Marker in Ovarian Cancer Patients Undergoing First-Line Treatment Plus Bevacizumab.Marina Fabbi, Delfina Costa, Daniela Russo
|Mar 23, 2022
Olaparib beyond progression compared with platinum chemotherapy after secondary cytoreductive surgery in patients with recurrent ovarian cancer: phase III randomized, open-label MITO 35b study, a project of the MITO-MANGO groups.Clorinda Schettino, Lucia Musacchio, Michele Bartoletti
|Apr 03, 2021
Prognostic Evidence of the miRNA-Based Ovarian Cancer Signature MiROvaR in Independent Datasets.Loris De Cecco, Marina Bagnoli, Paolo Chiodini
|Jan 04, 2021
Choline kinase alpha impairment overcomes TRAIL resistance in ovarian cancer cells.Andrea Rizzo, Alessandro Satta, Giulia Garrone
|Oct 20, 2020
Impact of COVID-19 in gynecologic oncology: a Nationwide Italian Survey of the SIGO and MITO groups.Giorgio Bogani, Giovanni Apolone, Antonino Ditto
|Apr 11, 2020
Ovarian Cancer Translational Activity of the Multicenter Italian Trial in Ovarian Cancer (MITO) Group: Lessons Learned in 10 Years of Experience.Daniela Califano, Daniela Russo, Giosuè Scognamiglio
Pageof 2
Frequent Collaborators
2 joint publications
Loris De Cecco
2 joint publications
Sandro Pignata
2 joint publications
Daniela Russo
2 joint publications
Silvana Canevari
2 joint publications
Mariangela Figini
2 joint publications
Antonella Tomassetti
2 joint publications
Daniela Califano
2 joint publications
Marina Bagnoli
1 joint publications
Barbara Frigerio
1 joint publications
Francesco Raspagliesi
